Chunsong Yang

Chunsong Yang

Auto-generated profile, based on publicly available information

Chunsong Yang

Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, PO Box 800733, Charlottesville, VA, 22908, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
CYChunsong Yang
Chunsong Yang
KWKrzysztof Wierbiłowicz
Krzysztof Wierbiłowicz
NDNatalia M. Dworak
Natalia M. Dworak
SBSong Yi Bae
Song Yi Bae
STSachi B. Tengse
Sachi B. Tengse
BPBryce M. Paschal
Bryce M. Paschal
The ADP-ribosyltransferase PARP7 modulates protein function by conjugating ADP-ribose to the side chains of acceptor amino acids. PARP7 has been shown to affect gene expression in prostate cancer cells and certain other cell types by mechanisms that include transcription factor ADP-ribosylation. Here, we use a recently developed catalytic inhibitor to PARP7, RBN2397, to study the effects of PARP7 inhibition in androgen receptor (AR)-positive and AR-negative prostate cancer cells. We find that RBN2397 has nanomolar potency for inhibiting androgen-induced ADP-ribosylation of the AR. RBN2397 inhibits the growth of prostate cancer cells in culture when cells are treated with ligands that activate the AR, or the aryl hydrocarbon receptor, and induce PARP7 expression. We show that the growth-inhibitory effects of RBN2397 are distinct from its enhancement of IFN signaling recently shown to promote tumor immunogenicity. RBN2397 treatment also induces trapping of PARP7 in a detergent-resistant fraction within the nucleus, which is reminiscent of how inhibitors such as talazoparib affect PARP1 compartmentalization. Because PARP7 is expressed in AR-negative metastatic tumors and RBN2397 can affect cancer cells through multiple mechanisms, PARP7 may be an actionable target in advanced prostate cancer.Significance: RBN2397 is a potent and selective inhibitor of PARP7 that reduces the growth of prostate cancer cells, including a model for treatment-emergent neuroendocrine prostate cancer. RBN2397 induces PARP7 trapping on chromatin, suggesting its mechanism of action might be similar to clinically used PARP1 inhibitors.

18 July 2025 in The EMBO Journal
Verified
Journal Article
Open access
KWKrzysztof Wierbiłowicz
Krzysztof Wierbiłowicz
CYChun-Song Yang
Chun-Song Yang
AAAhmed Almaghasilah
Ahmed Almaghasilah
PWPatryk A Wesołowski
Patryk A Wesołowski
PPPhilipp Pracht
Philipp Pracht
BPBryce M. Paschal
Bryce M. Paschal
The androgen receptor (AR) transduces the effects of circulating and tumor-derived androgens to the nucleus through ligand-induced changes in protein conformation, localization, and chromatin engagement. Defining how these events are integrated with signal transduction is critical to understand how AR drives prostate cancer and unveil pathway features that are potentially amenable to therapeutic intervention. We describe a novel post-transcriptional mechanism that controls AR levels on chromatin and gene output based on highly selective, inducible degradation. We find that the mono-ADP-ribosyltransferase PARP7 generates an ADP-ribosyl degron in the DNA-binding domain of AR, which is recognized by the ADP-ribose reader domain in the ubiquitin E3 ligase DTX2 and degraded by the proteasome. Mathematical modeling of the pathway suggested that PARP7 ADP-ribosylates chromatin-bound AR, a prediction that was validated in cells using an AR DNA-binding mutant. Non-conventional ubiquitin conjugation to ADP-ribosyl-cysteine and degradation by the proteasome forms the basis of a negative feedback loop that regulates modules of AR target genes. Our data expand the repertoire of mono-ADP-ribosyltransferases to include gene regulation via highly selective protein degradation.

29 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CVCarlos Vela-Rodríguez
Carlos Vela-Rodríguez
CYChunsong Yang
Chunsong Yang
HAHeli I. Alanen
Heli I. Alanen
RERebeka Eki
Rebeka Eki
Tarek AbbasTarek Abbas
Tarek Abbas
LLLari Lehtio
Lari Lehtio
Deltex proteins are a family of E3 ubiquitin ligases that encode C-terminal RING and DTC domains that mediate interactions with E2 ubiquitin-conjugating enzymes and recognise ubiquitination substrates. DTX3L is unique among the Deltex proteins based on its N-terminal domain architecture. The N-terminal D1 and D2 domains of DTX3L mediate homo-oligomerisation, and the D3 domain interacts with PARP9, a protein that contains tandem macrodomains with ADP-ribose reader function. While DTX3L and PARP9 are known to heterodimerize, they assemble into a high molecular weight oligomeric complex, but the nature of the oligomeric structure, including whether this contributes to the ADP-ribose reader function is unknown. Here, we report a crystal structure of the DTX3L N-terminal D2 domain and show that it forms a tetramer with, conveniently, D2 symmetry. We identified two interfaces in the structure: a major, conserved interface with a surface of 973 Å 2 and a smaller one of 415 Å 2 . Using native mass spectrometry, we observed molecular species that correspond to monomers, dimers and tetramers of the D2 domain. Reconstitution of DTX3L knockout cells with a D1-D2 deletion mutant showed the domain is dispensable for DTX3L-PARP9 heterodimer formation, but necessary to assemble an oligomeric complex with efficient reader function for ADP-ribosylated androgen receptor. Our results suggest that homo-oligomerisation of DTX3L is important for mono-ADP-ribosylation reading by the DTX3L-PARP9 complex and to a ligand-regulated transcription factor.

4 April 2023
Verified
Other
Open access
CYChunsong Yang
Chunsong Yang
KWKrzysztof Wierbilowicz
Krzysztof Wierbilowicz
NDNatalia M Dworak
Natalia M Dworak
SBSong Yi Bae
Song Yi Bae
STSachi B Tengse
Sachi B Tengse
BPBryce M. Paschal
Bryce M. Paschal
Cell cycle distributions of cell lines treated with RBN2397 plus androgen or plus AHR agonist

4 April 2023
Verified
Other
Open access
CYChunsong Yang
Chunsong Yang
KWKrzysztof Wierbilowicz
Krzysztof Wierbilowicz
NDNatalia M Dworak
Natalia M Dworak
SBSong Yi Bae
Song Yi Bae
STSachi B Tengse
Sachi B Tengse
BPBryce M. Paschal
Bryce M. Paschal
The ADP-ribosyltransferase PARP7 modulates protein function by conjugating ADP-ribose to the side chains of acceptor amino acids. PARP7 has been shown to affect gene expression in prostate cancer cells and certain other cell types by mechanisms that include transcription factor ADP-ribosylation. Here, we use a recently developed catalytic inhibitor to PARP7, RBN2397, to study the effects of PARP7 inhibition in androgen receptor-positive and androgen receptor-negative prostate cancer cells. We find that RBN2397 has nanomolar potency for inhibiting androgen-induced ADP-ribosylation of the androgen receptor. RBN2397 inhibits the growth of prostate cancer cells in culture when cells are treated with ligands that activate the androgen receptor, or the aryl hydrocarbon receptor, and induce PARP7 expression. We show that the growth inhibitory effects of RBN2397 are distinct from its enhancement of interferon signaling recently shown to promote tumor immunogenicity. RBN2397 treatment also induces trapping of PARP7 in a detergent-resistant fraction within the nucleus, which is reminiscent of how inhibitors such as Talazoparib affect PARP1 fractionation. Because PARP7 is expressed in AR negative metastatic tumors and RBN2397 can affect cancer cells through multiple mechanisms, PARP7 may be an actionable target in advanced prostate cancer.

4 April 2023
Verified
Other
Open access
CYChunsong Yang
Chunsong Yang
KWKrzysztof Wierbilowicz
Krzysztof Wierbilowicz
NDNatalia M Dworak
Natalia M Dworak
SBSong Yi Bae
Song Yi Bae
STSachi B Tengse
Sachi B Tengse
BPBryce M. Paschal
Bryce M. Paschal
Extendend analysis of PARP7 expression in prostate cancer